Skip to main content
Skip to content
Agentic Finance

How to Read an S-1 Prospectus in 45 Minutes: 20 Questions and a Free Evidence Checklist

Read an S-1 filing with 20 source-first checks covering pricing, share rights, dilution, risk, revenue, cash, commitments and final prospectus updates. Export your own DN evidence record.

Financial filing under magnifying glass with research checklist and data visuals
Reading options: audio, text size & sections

What Matters

The fastest way to misread an IPO is to treat the price, revenue growth, investor demand and company value as interchangeable. A Form S-1 gives you a structured way to test those claims, if you read the current version and distinguish what is documented from what remains unresolved.

DN research method: 20 questions, 4 review blocks, one private evidence record. This guide explains how to read an S-1 in a focused 45-minute session; 45 minutes is a planning framework, not a measured completion time.

Decision first. The objective is to determine what the company has proved, what it has merely represented, what you cannot yet know and which unanswered items would change your assessment. Do not turn this checklist into a stock rating.

The 45-minute reading plan

0–8 minutes: confirm the document version, registration status, offering mechanics and who receives proceeds (questions 1–5). 8–18 minutes: read the equity rights, dilution, lock-ups and core risk factors (6–9). 18–35 minutes: reconcile revenue, cost structure, adjusted metrics, cash flow and long-term obligations (10–17). 35–45 minutes: inspect related parties, underwriting, and the next update trigger (18–20). Allow substantially more time for complex disclosures or conflicting information.

The 20 questions and their evidence

1. Verify the latest filing

Where to look: Cover; EDGAR filing detail. Check the accession number, filed date, amendment number and any later filings. A filing you downloaded yesterday can already be superseded.

Do not infer: The first version may omit a price, underwriting terms or updated financial periods.

2. Is the registration effective?

Where to look: Cover and SEC effectiveness notices. Distinguish a submitted S-1/A from a registration statement that has become effective. The phrase ‘subject to completion’ is not final pricing.

Do not infer: An anticipated trading date is not proof of effectiveness or completed share issuance.

3. Who is actually selling?

Where to look: Cover and Selling Stockholders. Separate newly issued shares from secondary shares sold by existing holders. Company proceeds and insider liquidity are different economic events.

Do not infer: The public share count is not necessarily the post-offering shares outstanding.

4. What does the price range prove?

Where to look: Cover; Underwriting. Treat the indicative range as preliminary. Confirm the filed final prospectus and share count before calculating gross proceeds.

Do not infer: A midpoint is a scenario, not an execution price or expected return.

5. What is the use of proceeds?

Where to look: Use of Proceeds. Identify whether proceeds repay debt, support operating spending, fund acquisitions, or provide general corporate liquidity; distinguish specific commitments from discretionary language.

Do not infer: An announced raise is not necessarily funding for new growth projects.

6. How much dilution is there?

Where to look: Dilution; Capitalization. Record tangible book value, assumed price, changes in share count and options. Test whether employees’ and preferred holders’ conversions are included.

Do not infer: Headline market cap can omit options, convertibles or other dilutive securities.

7. Who controls the votes?

Where to look: Description of Capital Stock; Principal Stockholders. Map voting power, board election rights, protective provisions and related entities across every class. Do not equate identical economic percentages with identical control.

Do not infer: A company’s public-benefit status is not itself a shareholder voting right.

8. What restrictions apply to resale?

Where to look: Shares Eligible for Future Sale; Underwriting. Identify lock-ups, exceptions, waivers, registration rights and release timing. Label unknown dates as unknown until the terms are filed.

Do not infer: Lock-up expiry can increase sale eligibility without proving anyone will sell.

9. What could permanently impair the business?

Where to look: Risk Factors. Extract company-specific threats, not just the generic warning that prices are volatile. Record the mechanism, responsible party and plausible loss channel.

Do not infer: A risk disclosure does not quantify the probability of that loss.

10. How dependent is demand?

Where to look: Business; MD&A; revenue note. Check customer, sector, channel and reseller concentration with the same period and revenue definition. Where figures are missing, log the omission.

Do not infer: Fast growth does not prove that demand is diversified or repeatable.

11. What does revenue actually count?

Where to look: Revenue recognition policy; financial notes. Identify gross versus net presentation, token/usage billing, credits, reseller arrangements and whether revenue reflects delivered services.

Do not infer: A management run rate is not revenue recognised under financial reporting rules.

12. Are periods truly comparable?

Where to look: Selected periods; MD&A; statements. Align quarter, year-to-date and annual comparatives; check acquisitions, restatements and accounting changes before quoting growth.

Do not infer: Multiplying a quarter by four is a scenario, not audited annual revenue.

13. What happened to gross margin?

Where to look: Cost of revenue; income statements. Reconcile compute, serving, personnel, depreciation and partner arrangements to reported gross profit where disclosed.

Do not infer: Gross profit is not cash flow, and compute commitments may fall in other notes.

14. What is being adjusted away?

Where to look: Non-GAAP reconciliation; GAAP statements. Start with GAAP income, then list each non-GAAP adjustment and its economic implication—especially stock compensation and unusual credits.

Do not infer: A positive adjusted metric cannot be labeled GAAP profitability.

15. What is operating cash really doing?

Where to look: Cash flow statements; MD&A. Separate operating cash flows, capital investment, financing flows, collateral and working-capital movements. Note whether the period is cash-generative without new finance.

Do not infer: Financing proceeds can make a cash balance grow while operations consume cash.

16. What does the balance sheet owe?

Where to look: Balance sheet; debt and lease footnotes. Map debt, debt conversion, collateral, leases, accrued expenses and contingencies, distinguishing recognised liabilities from future commitments.

Do not infer: Not all contracted payments are immediately due or recognised as liabilities.

17. What is promised beyond the balance sheet?

Where to look: Commitments and Contingencies. Read purchase commitments, minimum spend, leases not yet commenced, power capacity and contingent trigger language; map scheduled years.

Do not infer: Do not sum overlapping tables or treat gross undiscounted obligations as one-year spending.

18. Are counterparties also financiers?

Where to look: Related Party; Major Customers; Underwriting. Separate customers, vendors, investors and placement participants where disclosures identify the relationship. Draw a relationship line only when documented.

Do not infer: An investor-vendor relationship is not by itself proof of circular or fabricated revenue.

19. What do underwriters and insiders receive?

Where to look: Underwriting; Selling Stockholders. Check discounts, fees, options, stabilization provisions, indemnities and selling-holder interests. Do the gross-to-net proceeds bridge.

Do not infer: A proposed over-allotment option is not exercised merely because it appears in the prospectus.

20. What will trigger the next audit?

Where to look: EDGAR filing history and final prospectus. Save the exact accession and document version. Watch for S-1/A, effectiveness, final 424B-series prospectus and the first quarterly reporting cycle.

Do not infer: A refreshed website does not mean underlying evidence has been updated.

DN S-1 Evidence Checklist: 20 source questions

A local research record, not a score for whether shares are worth buying. Mark each question documented, disputed or unknown. Unknown is not zero risk. Attach a citation or note for later review. No inputs are sent to DN.

Select evidence statuses and assess the record to enable the export.

Illustrative example labels are synthetic workflow demonstration, not a review of Anthropic or any other issuer. Instrument DN-S1E v1.0.0; record schema dn-s1-evidence-record/1.0.0.

A real example of why version control matters

Anthropic’s 17 November 2026 S-1/A amendment presents an indicated $70–$78 offer price, 825 million public shares, and separate issuer and selling-holder counts. These are terms as filed on that date, not guaranteed final terms. A later effective registration or final prospectus could supersede them. Use DN’s 15-number Anthropic S-1 analysis and offering bridge for a source-specific worked comparison. This article does not duplicate those company-specific calculations.

How to interpret your output

One documented item is not 5 points; an unknown item is not a failing grade; and a disputed claim is a request for investigation, not an allegation of fraud. The evidence record preserves your exact checked states, notes, source-review date and analysis timestamp separately. Use the exported JSON as a dated worksheet, not an endorsement.

Primary sources and review boundaries

Read the SEC’s registration statement guide, IPO investor bulletin, EDGAR research instructions and official Form S-1 instructions. The SEC says a registration statement has a prospectus and a separate Part II, and advises investors to read the most recent amendment rather than relying on preliminary pricing. Source review date: 18 November 2026. Only the Anthropic example references an identified company; all other worksheet examples are hypothetical, not tested company ratings.

Related research and a commercial option

DN’s pre-IPO markets guide explains why secondary shares, SPV claims, derivatives and exchange-traded common stock are not interchangeable. Readers who want market charting after a genuine listing can compare TradingView plans. That is a DN affiliate link; the platform does not provide IPO allocations through this referral and no brokerage eligibility is implied.

Frequently asked questions

Is an S-1 a recommendation to invest?

No. An S-1 is the issuer’s registration statement containing the prospectus, financial statements and risks. It does not independently determine whether a security fits your situation.

Does an amended S-1 mean the IPO price is final?

No. Check the latest prospectus and effectiveness, then the final prospectus, often filed under the 424B series, for final terms.

What is the difference between gross proceeds and issuer cash?

Gross public proceeds multiply sold shares by offer price; issuer cash excludes secondary seller proceeds and is reduced by applicable expenses.

Does an unknown field count as a negative result in the checklist?

No. Unknown denotes that the reader has not established the fact. It is never converted to zero, a passing grade or a presumed failure.

Disclosure and corrections

DN used AI-assisted drafting and checked the structural explanation against SEC investor education and Form S-1 instructions. This is not personalised investment, legal or tax advice, not a solicitation to acquire securities and not sponsored by an issuer. We may earn a referral commission from clearly identified commercial links. Send documentary corrections through DN’s contact page, citing the relevant filing and dated accession.

Get the most talked about stories directly in your inbox

Join the Decentralised News briefing for independent crypto, DeFi and AI analysis. No spam, unsubscribe anytime.